Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07466511

Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis

Researchers hypothesized that Bifidobacterium breve Supplement could reduce the progression rate of idiopathic scoliosis in children and potentially prevent the occurrence of new cases of scoliosis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

6 year–15 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Second Affiliated Hospital of Wenzhou Medical University, Zhejiang, Zhejiang 325000

Wenzhou, Zhejiang, 325600, China

Location contact

Xiangyang Wang

CONTACT

[email protected]

13506663458

About this study

Idiopathic scoliosis (IS) is a common pediatric disorder characterized by a spinal curvature exceeding 10 degrees that develops in the absence of obvious congenital or physiological defects. IS is highly prevalent during adolescence, afflicting 3-4% of children worldwide, yet the underlying causes remain poorly understood. Recent studies have indicated that children with idiopathic scoliosis have a disrupted gut microbiota, but there is currently no clinical data on the impact of any probiotic supplementation on scoliosis. Our unpublished data show that the abundance of probiotics such as Bifidobacterium breve in the intestines of children with idiopathic scoliosis is reduced, while the levels of multiple bile acids in the blood are elevated. Therefore, we hypothesize that Bifidobacterium breve supplementation can reduce the progression rate of idiopathic scoliosis in children and may have a potential role in preventing the onset of new cases of scoliosis in children.

This study is a single-blind, randomized controlled trial to investigate the effect of Bifidobacterium breve on the magnitude of idiopathic spinal curves. Eligible scoliosis children will be randomly assigned to one of two groups. The intervention group will receive oral supplementation of Bifidobacterium breve at 4.5x106 CFU daily for 6 months, along with a standardized gut microbiota-related health course for lifestyle correction (such as adjusting diet, moderate exercise, and reducing antibiotic abuse). The intervention group will be subject to regular phone follow-ups to inquire about probiotic intake and be encouraged to adhere to the regimen. The control group will receive the same health course but no probiotic supplementation, serving as an active control to account for the impact of lifestyle improvements. For all scoliosis children, routine follow-up visits will be scheduled every 6 months for at least 24 months to assess curve progression. Additionally, children who have not yet reached the scoliosis threshold at baseline will also be invited and randomly assigned to the same grouping scheme or simply followed up as observational subjects. All participating children, as part of a provincial health program in Zhejiang Province, will undergo annual scoliosis screening and clinical assessment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 6 to 15 years

Diagnosed with idiopathic scoliosis based on clinical evaluation and radiographic examination at the first clinic visit

Skeletally immature, defined as Risser sign 0 to 3

Major Cobb angle < 40 degrees at baseline

Written informed consent provided by the participant or legal guardian

Able and willing to comply with study procedures

Exclusion criteria

  • Plans to relocate within the next 24 months

Use of antibiotics, probiotics, hormones, immunosuppressants, or other nutritional supplements known to affect gut microbiota within the past 3 months or during the study period without investigator approval

Known allergy, sensitivity, or intolerance to the investigational product or its ingredients

Current or prior significant gastrointestinal disease requiring medication, or history of gastrointestinal surgery

Severe gastrointestinal symptoms such as persistent heartburn or indigestion

Musculoskeletal, neurodevelopmental, syndromic, or other conditions that may account for the spinal deformity

History of spine surgery or major spinal injury

Spinal tumor or malignant disease involving the spine

Leg length discrepancy > 20 mm

Severe chronic diseases that could interfere with study participation or outcome assessment, including but not limited to diabetes, narcolepsy, or poorly controlled asthma

Severe obesity, defined as BMI z-score ≥ 3

Treatment and study plan

Bifidobacterium breve

Dietary Supplement

Oral Bifidobacterium breve supplementation, 4.5 × 10^6 CFU daily for 6 months

Lifestyle Education

Behavioral

A standardized education session delivered at baseline on diet optimization, appropriate exercise, and avoidance of unnecessary antibiotic use.

Primary outcomes

  1. Change in Major Cobb Angle

    Time frame: Baseline and every 6 months up to 24 months

    Major curve magnitude will be measured on standing full-spine radiographs using the standard Cobb method.

  2. Change in Angle of Trunk Rotation (ATR)

    Time frame: Baseline and every 6 months up to 24 months

    Trunk asymmetry will be assessed using a scoliometer to measure angle of trunk rotation.

Secondary outcomes

  1. Scoliosis Research Society-22 (SRS-22) Questionnaire Score

    Time frame: Baseline and every 6 months up to 24 months

    Health-related quality of life will be assessed using the SRS-22 questionnaire, including pain, self-image, function, mental health, and treatment satisfaction.

  2. Gut Microbiota Composition

    Time frame: Baseline and Month 6

    Gut microbial composition in stool samples will be assessed using metagenomic sequencing or polymerase chain reaction methods.

  3. Gastrointestinal Symptoms

    Time frame: Baseline and Month 6

    Gastrointestinal symptoms and bowel movement frequency will be assessed through structured interview.

  4. Serum Bile Acid Levels

    Time frame: Baseline and Month 6

    Serum bile acid concentrations will be measured using blood samples collected from participants.

Study contacts

Contact information is provided by the study sponsor or research team.

Xiangyang Wang

CONTACT

[email protected]

13506663458

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital of Wenzhou Medical University

Other

Registry information

Official study title

Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis: A Prospective, Single-Blind, Randomized Controlled Trial

Important dates

Study start
2027
Primary completion
2030
Study completion
2030
First posted
Mar 12, 2026
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.